| 000 | 01683 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250517162408.0 | ||
| 264 | 0 | _c20191021 | |
| 008 | 201910s 0 0 eng d | ||
| 022 | _a1873-5576 | ||
| 024 | 7 |
_a10.2174/1568009617666170630124643 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSingh, Avineesh | |
| 245 | 0 | 0 |
_aThe Safety, Efficacy and Therapeutic Potential of Histone Deacetylase Inhibitors with Special Reference to Panobinostat in Gastrointestinal Tumors: A Review of Preclinical and Clinical Studies. _h[electronic resource] |
| 260 |
_bCurrent cancer drug targets _c2018 |
||
| 300 |
_a720-736 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 | _aAcetylation |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 |
_aDigestive System Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aDrug Combinations |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aHistone Deacetylase Inhibitors _xadverse effects |
| 650 | 0 | 4 |
_aHistone Deacetylases _xclassification |
| 650 | 0 | 4 |
_aHistones _xmetabolism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 |
_aPanobinostat _xadverse effects |
| 650 | 0 | 4 |
_aProteasome Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aPatel, Preeti | |
| 700 | 1 | _aPatel, Vijay Kumar | |
| 700 | 1 | _aJain, Deepak Kumar | |
| 700 | 1 | _aKamal, M | |
| 700 | 1 | _aRajak, Harish | |
| 773 | 0 |
_tCurrent cancer drug targets _gvol. 18 _gno. 8 _gp. 720-736 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2174/1568009617666170630124643 _zAvailable from publisher's website |
| 999 |
_c27330710 _d27330710 |
||